Cilostazol This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest news and research items in this category.

Suppression of PU.1‐linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis
Conclusions and ImplicationsCilostazol down‐regulated LPS‐stimulated PU.1‐linked TLR4 expression and TLR4/MyD88/NF‐κB signal pathways, and then suppressed inflammatory cytokine production in synovial macrophages from RA patients. Also cilostazol markedly inhibited the severity of CIA in mice. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - February 25, 2013 Category: Drugs & Pharmacology Authors: SY Park, SW Lee, SH Baek, CW Lee, WS Lee, BY Rhim, KW Hong, CD Kim Tags: Research Paper Source Type: research

Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis After Drug-Eluting Stent Implantation: A Meta-Analysis.
Abstract This meta-analysis was performed to compare the risk of cardiac events and restenosis between triple antiplatelet therapy (TAT, addition of cilostazol to aspirin and clopidogrel) and conventional dual antiplatelet therapy (DAT, aspirin and clopidogrel) in drug-eluting stents (DES) implantation patients. We performed PUBMED, MEDLINE, EMBASE, and Cochrane CENTRAL searches for randomized clinical trials of TAT versus DAT in patients after DES implantation. Five clinical trials were involved in the study. TAT was associated with a 36% reduction in major adverse cardiac events (MACE; odds ratio (OR) = 0.64;...
Source: The Journal of Clinical Pharmacology - February 22, 2013 Category: Drugs & Pharmacology Authors: Chen Z, Qian J, Chen Y, Ma J, Ge J Tags: J Clin Pharmacol Source Type: research

New horizons of acute myocardial infarction: from the Korea acute myocardial infarction registry.
Abstract As the first nationwide Korean prospective multicenter data collection registry, the Korea Acute Myocardial Infarction Registry (KAMIR) launched in November 2005. Through a number of innovative approaches, KAMIR suggested new horizons about acute myocardial infarction (AMI) which contains unique features of Asian patients from baseline characteristics to treatment strategy. Obesity paradox was existed in Korean AMI patients, whereas no gender differences among them. KAMIR score suggested new risk stratifying method with increased convenience and an enhanced accuracy for the prediction of adverse outcomes. ...
Source: J Korean Med Sci - February 1, 2013 Category: Journals (General) Authors: Lee KH, Jeong MH, Ahn Y, Cho MC, Kim CJ, Kim YJ Tags: J Korean Med Sci Source Type: research

Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes
In conclusion, EX and CIL have additive effects on IS limitation in diabetic mice. The additive effects are related to cAMP-induced PKA activation, as H-89 blocked the protective effect of CIL + EX. (Source: AJP: Heart and Circulatory Physiology)
Source: AJP: Heart and Circulatory Physiology - January 1, 2013 Category: Cardiology Authors: Ye, Y., Qian, J., Castillo, A. C., Ling, S., Ye, H., Perez-Polo, J. R., Bajaj, M., Birnbaum, Y. Tags: INTEGRATIVE CARDIOVASCULAR PHYSIOLOGY AND PATHOPHYSIOLOGY Source Type: research

Comparison of Antiplatelet and Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke in Patients With Peripheral Artery Disease.
Conclusions: Cilostazol and clopidogrel were more effective in preventing recurrent ischemic stroke without increased hemorrhagic events than aspirin in patients with PAD. PMID: 23269006 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - December 26, 2012 Category: Cardiology Authors: Lee WH, Chu CY, Hsu PC, Su HM, Lin TH, Voon WC, Lai WT, Sheu SH Tags: Circ J Source Type: research

Triple antiplatelet therapy with cilostazol: Hitting the “Sweet‐Spot”
(Source: Catheterization and Cardiovascular Interventions)
Source: Catheterization and Cardiovascular Interventions - December 26, 2012 Category: Cardiovascular & Thoracic Surgery Authors: Jorge A. Belardi, Mariano Albertal Tags: Coronary Artery Disease Source Type: research

Adjunctive Cilostazol versus High Maintenance Dose of Clopidogrel in Patients with Hyporesponsiveness to Chronic Clopidogrel Therapy.
Conclusion: Adjunctive cilostazol improved clopidogrel responsiveness better than the higher maintenance dose of clopidogrel in hyporesponsive patients with chronic clopidogrel therapy. PMID: 23225796 [PubMed - in process] (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 21, 2012 Category: Universities & Medical Training Authors: Lee GY, Hahn JY, Lee SY, Kim HJ, Kim JH, Lee SY, Song YB, Choi SH, Choi JH, Gwon HC Tags: Yonsei Med J Source Type: research

Effect of Cilostazol in Preventing Restenosis after Carotid Artery Stenting Using the Carotid Wallstent: A Multicenter Retrospective Study [INTERVENTIONAL]
CONCLUSIONS: The restenosis rate after CAS by using the CWS was 8.3%. CLZ was associated with significant inhibition of restenosis. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - December 13, 2012 Category: Radiology Authors: Takayama, K., Taoka, T., Nakagawa, H., Myouchin, K., Wada, T., Sakamoto, M., Furuichi, K., Iwasaki, S., Kurokawa, S., Kichikawa, K. Tags: INTERVENTIONAL Source Type: research

Cilostazol Strengthens Barrier Integrity in Brain Endothelial Cells.
Abstract We studied the effect of cilostazol, a selective inhibitor of phosphodiesterase 3, on barrier functions of blood-brain barrier (BBB)-related endothelial cells, primary rat brain capillary endothelial cells (RBEC), and the immortalized human brain endothelial cell line hCMEC/D3. The pharmacological potency of cilostazol was also evaluated on ischemia-related BBB dysfunction using a triple co-culture BBB model (BBB Kit™) subjected to 6-h oxygen glucose deprivation (OGD) and 3-h reoxygenation. There was expression of phosphodiesterase 3B mRNA in RBEC, and a significant increase in intracellular cyclic AMP (...
Source: Cellular and Molecular Neurobiology - December 7, 2012 Category: Cytology Authors: Horai S, Nakagawa S, Tanaka K, Morofuji Y, Couraud PO, Deli MA, Ozawa M, Niwa M Tags: Cell Mol Neurobiol Source Type: research

Restenosis: a challenge for vascular surgeon.
Abstract From the beginning of the cardiovascular surgery to the endovascular era restenosis represents the main problem of several spreading vascular disciplines. It can be considered as an excessive wound healing reaction of target vessel of revascularization procedures, that leads to a new narrowing of the vascular lumen. Restenosis still represents the main limiting factor of the long-term success of revascularization procedures. Prevention and strict follow-up are well established techniques in order to reduce restenosis rate and clinical impact of this condition. New drugs as cilostazol have been proven benef...
Source: The Journal of Cardiovascular Surgery - December 1, 2012 Category: Cardiovascular & Thoracic Surgery Authors: Setacci C, Castelli P, Chiesa R, Grego F, Simoni GA, Stella A, Galzerano G, Sirignano P, De Donato G, Setacci F Tags: J Cardiovasc Surg (Torino) Source Type: research

Effect of Cilostazol in the Treatment of Acute Ischemic Stroke in the Lenticulostriate Artery Territory
Eur Neurol 2013;69:122–128 (DOI:10.1159/000343799) (Source: European Neurology)
Source: European Neurology - November 28, 2012 Category: Neurology Source Type: research

Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs.
CONCLUSION: Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia and reperfusion in this model. PMID: 23117610 [PubMed - in process] (Source: Acta Cirurgica Brasileira)
Source: Acta Cirurgica Brasileira - November 1, 2012 Category: Surgery Authors: Moreira Neto AA, Souza Júnior SS, Capelozzi VL, Parra-Cuentas ER, Schmidt Júnior AF, Francisco Neto A, Rodrigues OR Tags: Acta Cir Bras Source Type: research

Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Eur Neurol 2013;69:33–40 (DOI:10.1159/000338247) (Source: European Neurology)
Source: European Neurology - October 31, 2012 Category: Neurology Source Type: research

Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia
Conclusion: Cilostazol may be associated with reduced restenosis, reocclusion and clinically driven TLR at 3 months after infrapopliteal angioplasty. (Source: European Journal of Vascular and Endovascular Surgery)
Source: European Journal of Vascular and Endovascular Surgery - October 29, 2012 Category: Surgery Authors: Y. Soga, O. Iida, D. Kawasaki, K. Hirano, T. Yamaoka, K. Suzuki Tags: Peripheral Arterial Disease Source Type: research

A Genetic Variant in DPP10 Linked to Inherited J-Wave Syndrome Associated with Sudden Cardiac Death by Augmentation of Kv4.3 Channel Current
Background: Mutations in genes encoding the α (KCND3) and β (KCNE3) subunits of genes encoding the cardiac transient outward potassium (Ito) have been associated with inherited cardiac arrhythmia syndromes such as Brugada syndrome (BrS) and sudden infant death syndromes (SIDS). Here, we identify and characterize a novel genetic variant in DPP10 associated with severe pediatric J-wave syndrome (JWS) characterized by early repolarization syndrome (ERS). Methods and Results: The proband, a 14-year-old female, presented with atrial fibrillation. At age 16 she developed accentuated J waves in all ECG leads and multiple epi...
Source: Heart Rhythm - October 26, 2012 Category: Cardiology Authors: H. Barajas-Martinez, D. Hu, R. Pfeiffer, E. Burashnikov, A. Powers, T.K. Knilans, C. Antzelevitch Tags: News from the Cardiac Electrophysiology Society Source Type: research

Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia.
CONCLUSION: Cilostazol may be associated with reduced restenosis, reocclusion and clinically driven TLR at 3 months after infrapopliteal angioplasty. PMID: 23107298 [PubMed - as supplied by publisher] (Source: PubMed: Eur J Vasc Endovasc ...)
Source: PubMed: Eur J Vasc Endovasc ... - October 26, 2012 Category: Surgery Authors: Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K Tags: Eur J Vasc Endovasc Surg Source Type: research

Phosphodiesterase-3 Inhibition Augments the Myocardial Infarct Size Limiting Effects of Exenatide in Mice with Type-2 Diabetes.
Conclusions: EX and CIL have additive effects on IS limitation in diabetic mice. The additive effects are related to cAMP induced PKA activation, as H89 blocked the protective effect of CIL+EX. PMID: 23103492 [PubMed - as supplied by publisher] (Source: American Journal of Physiology. Heart and Circulatory Physiology)
Source: American Journal of Physiology. Heart and Circulatory Physiology - October 26, 2012 Category: Physiology Authors: Ye Y, Qian J, Castillo AC, Ling S, Ye H, Perez-Polo JR, Bajaj M, Birnbaum Y Tags: Am J Physiol Heart Circ Physiol Source Type: research

Patients with Good Collateralization May Profit from Cilostazol
Cardiology 2012;123:142 (DOI:10.1159/000342276) (Source: Cardiology)
Source: Cardiology - October 23, 2012 Category: Cardiology Source Type: research

Suppression of PU.1‐linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from rheumatoid arthritis patients
Conclusions and ImplicationsCilostazol down‐regulates LPS‐stimulated PU.1‐linked TLR4 expression and TLR4/MyD88/NF‐κB signal pathways, and then suppresses inflammatory cytokine production in synovial macrophages from RA patients. Consequently, cilostazol strongly inhibits the severity of CIA in mice. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - October 18, 2012 Category: Drugs & Pharmacology Authors: SY Park, SW Lee, SH Baek, CW Lee, WS Lee, BY Rhim, KW Hong, CD Kim Tags: Research Paper Source Type: research

TCT-735 Pharmacodynamic Effect of Adjunctive Cilostazol vs. High-dos Clopidogrel in Acute Coronary Syndrome Patients According to the CYP2C19 Genotype (ACCEL-GENOTYPE) study
(Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 16, 2012 Category: Radiology Source Type: research

Drug–drug interaction study to assess the effects of atorvastatin co‐administration on pharmacokinetics and anti‐thrombotic properties of cilostazol in male Wistar rats
ABSTRACT Cilostazol (CLZ) and atorvastatin (ATV) are often co‐prescribed to treat conditions such as peripheral arterial disease. In the present study, the drug–drug interaction potential of multi‐dose ATV co‐administration with CLZ on both pharmacokinetics and the anti‐thrombotic property of CLZ is demonstrated. The pharmacokinetic parameters of CLZ (6 mg/kg, twice daily) were determined in male Wistar rats after 7 days co‐administration with ATV (5 mg/kg, once daily) in order to assess the interaction potential between CLZ and ATV on chronic treatment. In vitro metabolic inhibition and everted gut sac s...
Source: Biopharmaceutics and Drug Disposition - October 7, 2012 Category: Drugs & Pharmacology Authors: Rahul Vats, Kanthikiran V. S. Varanasi, Rambabu Arla, Sridhar Veeraraghvan, Shraddha Rajak Tags: Original Paper Source Type: research

Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial.
Conclusions Oral administration of cilostazol is effective in preventing cerebral vasospasm with a low risk of severe adverse events. Clinical trial registration no. UMIN000004347, University Hospital Medical Information Network Clinical Trials Registry. PMID: 23039152 [PubMed - as supplied by publisher] (Source: Journal of Neurosurgery)
Source: Journal of Neurosurgery - October 5, 2012 Category: Neurosurgery Authors: Senbokuya N, Kinouchi H, Kanemaru K, Ohashi Y, Fukamachi A, Yagi S, Shimizu T, Furuya K, Uchida M, Takeuchi N, Nakano S, Koizumi H, Kobayashi C, Fukasawa I, Takahashi T, Kuroda K, Nishiyama Y, Yoshioka H, Horikoshi T Tags: J Neurosurg Source Type: research

Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication
Conclusion:Naftidrofuryl oxalate and cilostazol are both effective treatments for claudication; naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events. Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. (Source: British Journal of Surgery)
Source: British Journal of Surgery - October 3, 2012 Category: Surgery Authors: J. W. Stevens, E. Simpson, S. Harnan, H. Squires, Y. Meng, S. Thomas, J. Michaels, G. Stansby Tags: Meta‐Analysis Source Type: research

Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
CONCLUSION: Naftidrofuryl oxalate and cilostazol are both effective treatments for claudication; naftidrofuryl oxalate is likely to be the most effective, with minimal serious adverse events. Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd. PMID: 23034699 [PubMed - as supplied by publisher] (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - October 3, 2012 Category: Surgery Authors: Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G Tags: Br J Surg Source Type: research

Carbazepine/cilostazol: Drug-induced hypersensitivity/DRESS syndrome: case report
(Source: Reactions)
Source: Reactions - September 28, 2012 Category: Drugs & Pharmacology Tags: Short communication Source Type: research

Predictors of Recurrent Stroke in Patients With Symptomatic Intracranial Arterial Stenosis [Brief Reports]
Conclusion— Subcorticocortical lesions and multiple lesions are radiological predictors of recurrent ischemic stroke in symptomatic patients with intracranial arterial stenosis. Clinical Trial Registration— URL: www.clinicaltrials.gov. Unique identifier: NCT00130039. (Source: Stroke)
Source: Stroke - September 24, 2012 Category: Neurology Authors: Jung, J.-M., Kang, D.-W., Yu, K.-H., Koo, J.-s., Lee, J.-H., Park, J.-M., Hong, K.-S., Cho, Y.-J., Kim, J. S., Kwon, S. U., on behalf of the TOSS-2 Investigators Tags: Acute Cerebral Infarction Brief Reports Source Type: research

Characterization of New Organic Nitrate Hybrid Drugs Covalently Bound to Valsartan and Cilostazol
Pharmacology 2012;90:193–204 (DOI:10.1159/000339861) (Source: Karger Publishers)
Source: Karger Publishers - September 12, 2012 Category: Cancer & Oncology Source Type: research

Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers
Abstract Sarpogrelate and cilostazol are two commonly used adjunctive antiplatelet agents that also can be used to improve endothelial dysfunction. We compared the effects of sarpogrelate and cilostazol on endothelial dysfunction in active male smokers with flow-mediated dilatation (FMD). We enrolled and compared baseline and follow-up FMD in 20 young male smokers without any known cardiovascular diseases. Two participants who were initially medicated with cilostazol dropped out because of severe headache after taking medication. However, they continued the other experiment with sarpogrelate medication. Base...
Source: Heart and Vessels - September 11, 2012 Category: Cardiology Tags: Heart and Vessels Source Type: research

Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus
Conclusion MK and Cil have additive IS-limiting effects in diabetic mice. The additive effects are associated with an increase in myocardial cAMP levels and PKA activity with downstream phosphorylation of Akt, eNOS, 5-lipoxygenase and CREB and downregulation of PTEN expression. Content Type Journal ArticlePages 1-12DOI 10.1007/s10557-012-6409-xAuthors Yochai Birnbaum, The Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, USAAlexander C. Castillo, The Department of Biochemistry and Molecular Biology, University of Texas Med...
Source: Cardiovascular Drugs and Therapy - August 30, 2012 Category: Cardiology Tags: Cardiovascular Drugs and Therapy Source Type: research

Angiographic Restenosis and Its Clinical Impact after Infrapopliteal Angioplasty
Conclusion: The extremely high angiographic restenosis rate after infrapopliteal angioplasty may adversely impact clinical status improvement. (Source: European Journal of Vascular and Endovascular Surgery)
Source: European Journal of Vascular and Endovascular Surgery - August 30, 2012 Category: Surgery Authors: O. Iida, Y. Soga, D. Kawasaki, K. Hirano, T. Yamaoka, K. Suzuki, Y. Miyashita, H. Yokoi, M. Takahara, M. Uematsu Tags: Peripheral Arterial Disease Source Type: research

Angiographic Restenosis and Its Clinical Impact after Infrapopliteal Angioplasty.
CONCLUSION: The extremely high angiographic restenosis rate after infrapopliteal angioplasty may adversely impact clinical status improvement. PMID: 22938944 [PubMed - as supplied by publisher] (Source: PubMed: Eur J Vasc Endovasc ...)
Source: PubMed: Eur J Vasc Endovasc ... - August 28, 2012 Category: Surgery Authors: Iida O, Soga Y, Kawasaki D, Hirano K, Yamaoka T, Suzuki K, Miyashita Y, Yokoi H, Takahara M, Uematsu M Tags: Eur J Vasc Endovasc Surg Source Type: research

Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.
CONCLUSIONS: There is limited evidence suggesting that restenosis/reocclusion at six months following peripheral endovascular treatment is reduced by use of antiplatelet drugs compared with placebo/control, but associated information on bleeding and gastrointestinal side effects is lacking. There is also some evidence of variation in effect according to different drugs with cilostazol reducing reocclusion/restenosis at 12 months compared with ticlopidine and both LMWH and batroxobin combined with aspirin appearing beneficial compared with aspirin alone. However, available trials are generally small and of variable quality ...
Source: Cochrane Database of Systematic Reviews - August 23, 2012 Category: Journals (General) Authors: Robertson L, Ghouri MA, Kovacs F Tags: Cochrane Database Syst Rev Source Type: research

Predictors of Recurrent Stroke in Patients With Symptomatic Intracranial Arterial Stenosis.
CONCLUSIONS: Subcorticocortical lesions and multiple lesions are radiological predictors of recurrent ischemic stroke in symptomatic patients with intracranial arterial stenosis.Clinical Trial Registration-www.clinicaltrials.gov. Unique identifier: NCT00130039. PMID: 22910894 [PubMed - as supplied by publisher] (Source: Stroke)
Source: Stroke - August 21, 2012 Category: Neurology Authors: Jung JM, Kang DW, Yu KH, Koo JS, Lee JH, Park JM, Hong KS, Cho YJ, Kim JS, Kwon SU, on behalf of the TOSS-2 Investigators Tags: Stroke Source Type: research

Combination of cilostazol and clopidogrel attenuates Rat critical limb ischemia
Conclusion: Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI. (Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - August 16, 2012 Category: Research Authors: Jiunn-Jye SheuKun-Chen LinChing-Yen TsaiTzu-Hsien TsaiSteve LeuChia-Hung YenYung-Lung ChenHsueh-Wen ChangCheuk-Kwan SunSarah ChuaJenq-Lin YangHon-Kan Yip Source Type: research

Cilostazol Prevents Progression of Asymptomatic Carotid Artery Stenosis in Patients with Contralateral Carotid Artery Stenting [EXTRACRANIAL VASCULAR]
CONCLUSIONS: A higher degree of initial stenosis is associated with progression of asymptomatic ICS. Cilostazol may reduce the rate of disease progression in patients with asymptomatic ICS. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - August 14, 2012 Category: Radiology Authors: Kato, T., Sakai, H., Takagi, T., Nishimura, Y. Tags: EXTRACRANIAL VASCULAR Source Type: research

Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention.
CONCLUSIONSAmong T2DM patients, adding cilostazol achieves greater platelet inhibition compared with clopidogrel (150 mg/d), which is not influenced by genetic polymorphisms. PMID: 22837373 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - July 26, 2012 Category: Endocrinology Authors: Jeong YH, Tantry US, Park Y, Kwon TJ, Park JR, Hwang SJ, Bliden KP, Koh EH, Kwak CH, Hwang JY, Kim S, Gurbel PA Tags: Diabetes Care Source Type: research

A Meta-Analysis of Randomized Controlled Trials Appraising the Efficacy and Safety of Cilostazol after Coronary Artery Stent Implantation
Cardiology 2012;122:133–143 (DOI:10.1159/000339238) (Source: Cardiology)
Source: Cardiology - July 23, 2012 Category: Cardiology Source Type: research

Cilostazol-Based Triple Antiplatelet Therapy Compared to Dual Antiplatelet Therapy in Patients with Coronary Stent Implantation: A Meta-Analysis of 5,821 Patients
Cardiology 2012;122:148–157 (DOI:10.1159/000338812) (Source: Cardiology)
Source: Cardiology - July 23, 2012 Category: Cardiology Source Type: research

Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties
Abstract: Background and purpose: Brain microvascular disorders, including cerebral microscopic hemorrhage, have high prevalence but few treatment options. To develop new strategies for these disorders, we analyzed the effects of several phosphodiesterase (PDE) inhibitors on human brain microvascular endothelial cells (HBECs).Methods: We modified barrier properties and response to histamine of HBECs using cilostazol (PDE3 inhibitor), rolipram (PDE4 inhibitor), and dipyridamole (non-specific PDE inhibitor).Results: Cilostazol and dipyridamole altered the distribution of endothelial F-actin. Cilostazol increased expression o...
Source: Journal of the Neurological Sciences - July 23, 2012 Category: Neurology Authors: Shuo Liu, Chuanhui Yu, Fan Yang, Annlia Paganini-Hill, Mark J. Fisher Tags: Original Articles Source Type: research

Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients
This study shows that cilostazol causes a significant regression in carotid IMT in symptomatic stroke patients. Content Type Journal ArticleCategory Original CommunicationPages 1-9DOI 10.1007/s00415-012-6599-yAuthors Sung Hyuk Heo, Department of Neurology, Kyung Hee University Hospital, #1, Hoegi-dong, Dongdaemun-gu, Seoul, 130-702 KoreaJi Sung Lee, Department of Biostatistics, Korea University, Seoul, KoreaBeom Joon Kim, Department of Neurology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, KoreaKyoung Jin Hwang, Department of Neurology, Kyung Hee University Hospital, #1, Hoegi-dong, Dongda...
Source: Journal of Neurology - July 20, 2012 Category: Neurology Tags: Journal of Neurology Source Type: research

Liquid Chromatography - Tandem Mass Spectrometry for the Simultaneous Quantitation of Glipizide, Cilostazol and its Active Metabolite 3, 4-dehydro-cilostazol in Rat Plasma: Application for a Pharmacokinetic Study.
Abstract A liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) method for the simultaneous quantitation of glipizide, cilostazol and 3, 4-dehydro-cilostazol in rat plasma was developed and validated. Glimepride was used as an internal standard (IS). The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×4.6 mm i. d., 5 µ) using acetonitrile: 2 mM ammonium acetate buffer, pH 3.2 (90:10, v/v) as mobile phase at a flow rate 0.4 mL/min in an isocratic mode. Selective reaction monitoring was performed using the tran...
Source: Arzneimittel-Forschung - July 20, 2012 Category: Drugs & Pharmacology Authors: Satheeshmanikandan TR, Sridhar V, Kanthikiran VV, Swaroopkumar VV, Mukkanti K Tags: Arzneimittelforschung Source Type: research

Triple vs. Dual Antiplatelet Therapy in Patients With Acute Myocardial Infarction and Renal Dysfunction.
Conclusions: In AMI patients with renal dysfunction, triple antiplatelet therapy has a favorable in-hospital and short-term MACE impact, but it does not have an impact on the 1-year MACE-free survival. PMID: 22785460 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - July 3, 2012 Category: Cardiology Authors: Choi YH, Suh SH, Choi JS, Kim CS, Sim DS, Bae EH, Lim SY, Ma SK, Jeong MH, Kim SW, for the Korea Acute Myocardial Infarction Registry Investigators Tags: Circ J Source Type: research

Cilostazol and Primary-PCI: Mirage or Good Alternative?
Abstract Oral anti-platelet agents targeting the platelet P2Y12 receptor are an integral component of treating patients undergoing percutaneous coronary interventions. Advancements in the design of stents and catheters are pushing the technique towards treatment of high risk lesions whose failure would expose patients to catastrophic events. Success of these complex procedures largely lays on efficacy of anti-platelet drugs and the limitation of stent restenosis and/or thrombosis. Clopidogrel has been the most commonly used agent in this respect worldwide. However, there are certain shortcomings of clopidogrel, the...
Source: Current Vascular Pharmacology - July 1, 2012 Category: Drugs & Pharmacology Authors: Porto I, D'Amario D, Crea F Tags: Curr Vasc Pharmacol Source Type: research

Cilostazol and Diltiazem Attenuate Cyclosporine-Induced Nephrotoxicity in Rats
Conclusion: Cilostazol and especially diltiazem were effective to mitigate renal ischemia-reperfusion injury. (Source: Transplantation Proceedings)
Source: Transplantation Proceedings - July 1, 2012 Category: Transplant Surgery Authors: M. Gokce, M.F. Yuzbasioglu, E. Bulbuloglu, H. Oksuz, S. Yormaz, O. Altınoren, M. Kutlucan, I. Coskuner, E. Silay, I.T. Kale Tags: Experimental Studies Source Type: research

Drug‐drug interaction study to assess the effects of atorvastatin co‐administration on pharmacokinetics and anti‐thrombotic properties of cilostazol in male Wistar rats
ABSTRACT Cilostazol (CLZ) and atorvastatin (ATV) are often co‐prescribed to treat conditions such as peripheral arterial disease. In the present study, the drug–drug interaction potential of multi‐dose ATV co‐administration with CLZ on both pharmacokinetics and the anti‐thrombotic property of CLZ is demonstrated. The pharmacokinetic parameters of CLZ (6 mg/ kg, twice daily) were determined in male Wistar rats after 7 days co‐administration with ATV (5 mg/ kg, once daily) in order to assess the interaction potential between CLZ and ATV on chronic treatment. In‐vitro metabolic inhibition and everted gut s...
Source: Biopharmaceutics and Drug Disposition - July 1, 2012 Category: Drugs & Pharmacology Authors: Rahul Vats, Kanthikiran V. S. Varanasi, Rambabu Arla, Sridhar Veeraraghvan, Shraddha Rajak Tags: Original Paper Source Type: research

Cilostazol in NICE guideline
To the Editor Shalhoub and Davies1 commented in their summary of the National Institute for Health and Clinical Excellence (NICE) guidance on cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication (NICE technology appraisal guidance 223; available at: http://www.nice.org.uk/guidance/TA223) that the cost-effectiveness analysis was based on appropriate assumptions; however, this analysis was based on a meta-analysis plagued with uncertainties.2 In this evaluation, Squires et al2 systematically reviewed all randomised clinical trials for these drugs and obtaine...
Source: Heart - June 27, 2012 Category: Cardiology Authors: Bellmunt, S., Roset, P. N., Escudero, J. R. Tags: PostScript Source Type: research

Platelet aggregometry in the presence of PGE1 provides a reliable method for cilostazol monitoring
Conclusions: AA-induced platelet aggregation in the presence of 30nM PGE1 could give good estimate on plasma concentrations of cilostazol. It is suggested that this system is a good tool for monitoring cilostazol. (Source: Thrombosis Research)
Source: Thrombosis Research - June 25, 2012 Category: Hematology Authors: Kaneo Satoh, Isao Fukasawa, Kazuya Kanemaru, Shigemi Yoda, Yukio Kimura, Osamu Inoue, Masato Ohta, Hiroyuki Kinouchi, Yukio Ozaki Tags: Platelets and Cell Biology Source Type: research

Pancreatic β‐cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes
ConclusionOur results suggest that in islets from type 2 diabetes, stimulatory effects in certain cAMP‐compartments induced by PDE inhibitors might play a central role in the suppression of iNOS, resulting in increased β‐cell viability and improved secretory response to glucose. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - June 11, 2012 Category: Endocrinology Authors: Sarheed J. Muhammed, Ingmar Lundquist, Albert Salehi Tags: Original Article Source Type: research

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study
Conclusion: These findings suggest that cilostazol might have a preventive effect on cognitive decline in patients with AD and CVD. Geriatr Gerontol Int 2012; ••: ••–••. (Source: Geriatrics and Gerontology International)
Source: Geriatrics and Gerontology International - June 4, 2012 Category: Geriatrics Authors: Hirofumi Sakurai, Haruo Hanyu, Tomohiko Sato, Kazumasa Kume, Kentaro Hirao, Hidekazu Kanetaka, Toshihiko Iwamoto Source Type: research

Use of cilostazol in percutaneous coronary interventions.
CONCLUSIONS: Triple therapy with cilostazol has been shown to reduce MACEs by providing increased inhibition of platelet aggregation and reducing the rates of instent thrombosis compared to DAT without increasing the risk of bleeding complications. Further studies are needed to identify proper patient selection based on risk factors for the addition of cilostazol. Additionally, studies comparing cilostazol with newer antiplatelet therapies, such as prasugrel and ticagrelor, are needed. PMID: 22669796 [PubMed - in process] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - June 1, 2012 Category: Drugs & Pharmacology Authors: Rogers KC, Faircloth JM, Finks SW Tags: Ann Pharmacother Source Type: research